FDA Class I Recall: SAINI TRADE INC's ELECTRO BUZZ Tainted with Undeclared APIs, Posing Severe Risk
SAINI TRADE INC has initiated a nationwide Class I recall for its ELECTRO BUZZ dietary supplement due to undeclared chloropretadalafil, propoxyphenylsildenafil, and sildenafil. This poses a severe health risk, necessitating immediate action from procurement, regulatory, and supply chain leaders to scrutinize ingredient sourcing and ensure robust compliance frameworks against adulterated products.
FDA Class I Recall: Undeclared APIs in SAINI TRADE INC's ELECTRO BUZZ
The U.S. Food and Drug Administration (FDA) has classified the recall of SAINI TRADE INC's product, ELECTRO BUZZ Dietary Supplement, as Class I, indicating a high probability of serious adverse health consequences or death. This nationwide voluntary recall, identified as D-0465-2025, was initiated by SAINI TRADE INC on April 14, 2025, following laboratory analysis that confirmed the product was tainted with undeclared active pharmaceutical ingredients (APIs): chloropretadalafil, propoxyphenylsildenafil, and sildenafil. The product, packaged as 10 capsules per box with UPC B0DK68LF6J, was distributed by Health Fixer in Tempe, AZ 85288. The specific lot affected is KT-1ST-43-01-07/2024, with an expiration date of October 15, 2026. The primary regulatory violation cited is that ELECTRO BUZZ was marketed without an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA), a fundamental requirement for products containing drug substances. For procurement directors and supply chain VPs, this event underscores the severe risks associated with inadequate ingredient verification, particularly within the dietary supplement market. The presence of undeclared APIs like sildenafil and its analogues not only constitutes a major regulatory breach but also exposes consumers to potentially dangerous drug interactions and side effects, especially for individuals with pre-existing medical conditions or those on nitrate medications. Businesses must recognize that such adulteration can lead to significant reputational damage, costly product withdrawals, and potential legal liabilities. Robust due diligence and analytical testing protocols are no longer optional but essential safeguards against such critical supply chain failures.
SAINI TRADE INC Profile: Distribution of Adulterated Dietary Supplements
SAINI TRADE INC, operating from 1405 N Scottsdale Rd, Tempe, AZ 85288-1714, United States, is the recalling firm responsible for the ELECTRO BUZZ dietary supplement. While the product was distributed by Health Fixer, SAINI TRADE INC initiated the voluntary recall of 300 boxes of the product. This incident highlights the critical need for all entities within the distribution chain to maintain stringent quality control and regulatory compliance, regardless of their specific role. The product, marketed as a dietary supplement, was found to contain pharmaceutical-grade compounds, blurring the line between a supplement and an unapproved drug. For business development executives, this case illustrates the inherent risks in the rapidly expanding dietary supplement sector, particularly in categories prone to adulteration. The commercial implications extend beyond the recalling firm, as consumer trust in the broader dietary supplement market can erode when such incidents occur. Companies involved in sourcing, manufacturing, or distributing dietary supplements must ensure their internal processes and third-party partnerships are robust enough to prevent the introduction of undeclared substances. Regulatory affairs heads must educate their teams on the precise definitions and requirements distinguishing dietary supplements from drugs, as misclassification can lead to severe regulatory penalties and market access restrictions.
Supply Chain Exposure: Mitigating Risks from Undeclared Pharmaceutical Ingredients
The recall of ELECTRO BUZZ due to undeclared chloropretadalafil, propoxyphenylsildenafil, and sildenafil presents a significant supply chain exposure risk for any company operating in the dietary supplement or over-the-counter (OTC) product space. These compounds are phosphodiesterase-5 (PDE5) inhibitors, a class of drugs typically prescribed for erectile dysfunction. Their undeclared presence poses serious health risks, including dangerously low blood pressure, especially when combined with nitrates used for heart conditions, or other medications. The Class I classification by the FDA underscores the severity of this risk. Procurement directors must immediately assess their current supplier qualification programs. This incident necessitates a re-evaluation of analytical testing protocols for all raw materials and finished products, particularly those sourced from less transparent supply chains or regions with lax regulatory oversight. Relying solely on Certificates of Analysis (CoAs) from suppliers is insufficient; independent third-party testing for known adulterants and unexpected compounds is crucial. Supply chain VPs should implement enhanced traceability systems to quickly identify and isolate affected products, minimizing the impact of potential recalls. Failure to do so exposes businesses to not only regulatory enforcement but also class-action lawsuits and irreversible brand damage, impacting long-term market share and profitability.
Strategic Sourcing: Ensuring Authenticity and Compliance in Ingredient Supply
Given the recall of ELECTRO BUZZ, identifying and qualifying legitimate alternative suppliers for ingredients, particularly those used in health and wellness products, becomes paramount for procurement teams. While the specific undeclared APIs (chloropretadalafil, propoxyphenylsildenafil, sildenafil) are unapproved for dietary supplements, the broader implication is the need for rigorous sourcing of *any* ingredient. Companies must prioritize suppliers with a demonstrated history of cGMP compliance and robust quality management systems. This includes comprehensive documentation, audit trails, and a willingness to undergo independent audits. For regulatory affairs heads, establishing clear specifications for all incoming materials, including testing for known and potential adulterants, is non-negotiable. This proactive approach mitigates the risk of inadvertently incorporating unapproved drug substances into products. Business development executives exploring new product lines or markets within the dietary supplement space must factor in the heightened regulatory scrutiny and the cost of stringent quality assurance. Investing in in-house analytical capabilities or partnering with accredited laboratories for advanced testing, such as LC-MS/MS, is a critical investment to safeguard product integrity and consumer safety, ultimately protecting the company's market position and avoiding costly recalls.
Broader Regulatory Landscape: FDA's Vigilance on Adulterated Supplements
While specific prior actions for SAINI TRADE INC are not available in the knowledge graph, this Class I recall of ELECTRO BUZZ is consistent with the FDA's ongoing and aggressive enforcement against dietary supplements found to contain undeclared pharmaceutical ingredients. The agency consistently issues warnings and initiates recalls for products marketed as 'natural' or 'herbal' but secretly laced with potent, unapproved drugs. This pattern of enforcement highlights a systemic risk across the dietary supplement industry, particularly in categories like sexual enhancement, weight loss, and bodybuilding. Recent parallel events, such as the FDA Class II Recall of Essential Wellness Pharma's Progesterone Injection in June 2026 for sterility issues, and the FDA hearing concerning Amgen's Tavneos market future, underscore the agency's broad and active regulatory oversight across the pharmaceutical and health product sectors. While these events differ in nature, they collectively signal an environment of heightened scrutiny. Regulatory affairs heads must interpret this as a clear directive to enhance internal compliance programs, conduct regular risk assessments of their product portfolios, and monitor FDA guidance and enforcement trends closely. The commercial imperative is to avoid becoming another statistic in the FDA's public database of adulterated products, which can severely impact market access and investor confidence.
Recall Progression and Future Compliance Imperatives for the Industry
The recall of ELECTRO BUZZ by SAINI TRADE INC remains ongoing, with the FDA's Center for Drug Evaluation and Research (CDER) classifying it on June 11, 2025, after the firm's initial notification via letter on April 14, 2025. The FDA will continue to monitor the effectiveness of this recall, ensuring that the 300 boxes of the adulterated product are removed from nationwide distribution. The agency's oversight extends beyond the immediate recall; it will likely scrutinize SAINI TRADE INC's manufacturing and quality control processes to determine the root cause of the adulteration and prevent recurrence. This could lead to further enforcement actions, including a Warning Letter, injunctions, or even criminal prosecution, depending on the findings. For regulatory affairs heads and business development executives, this ongoing event serves as a critical reminder of the need for proactive compliance. Companies must establish robust post-market surveillance systems to detect and respond to product issues swiftly. Supply chain VPs need to ensure that their recall procedures are well-rehearsed and capable of executing a rapid, comprehensive market withdrawal. The long-term implication for SAINI TRADE INC, and by extension, any firm facing similar issues, is increased regulatory burden, potential import alerts if products are sourced internationally, and a significant challenge in rebuilding consumer and regulatory trust. This incident reinforces the commercial necessity of an uncompromised commitment to product safety and regulatory adherence.